Transthyretin-mediated Amyloid Cardiomyopathy
📧 Sign up to get email alerts when something new happens for Transthyretin-mediated Amyloid Cardiomyopathy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-25Clinical Trial Update: CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) [Phase 3]
Phase 3 study of eplontersen in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) has completed.
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) [Phase 3]
An extension study to evaluate the long-term safety of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM); i…
-
CLINICAL_TRIALS research · 2025-11-28Clinical Trial Update: The CARDIO-TTRansform Scintigraphy Sub-study
An update on the CARDIO-TTRansform scintigraphy sub-study for transthyretin-mediated amyloid cardiomyopathy; the study is currently active b…
-
CLINICAL_TRIALS trial_result · 2025-11-28Clinical Trial Update: CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study
This update describes the CARDIO-TTRansform MRI sub-study for transthyretin-mediated amyloid cardiomyopathy sponsored by Ionis Pharmaceutica…
-
CLINICAL_TRIALS other · 2025-08-08Clinical Trial Update: CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) [Phase 3]
Phase 3 trial CARDIO-TTRansform evaluating Eplontersen for transthyretin-mediated amyloid cardiomyopathy is currently active but not recruit…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.